Piper Jaffray Companies restated their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a report issued on Monday, December 16th, Stock Target Advisor reports. They currently have a $104.00 price objective on the stock.
CRSP has been the topic of several other reports. Canaccord Genuity increased their price target on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the company a positive rating in a research note on Wednesday, November 20th. Roth Capital upped their target price on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. Oppenheimer raised their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the stock an outperform rating in a research note on Monday, November 25th. TheStreet upgraded shares of Crispr Therapeutics from a d rating to a c rating in a research report on Monday, October 28th. Finally, BidaskClub lowered shares of Crispr Therapeutics from a strong-buy rating to a buy rating in a research note on Friday, December 13th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $71.38.
Crispr Therapeutics stock opened at $67.23 on Monday. The stock has a market cap of $3.75 billion, a price-to-earnings ratio of -19.54 and a beta of 3.31. Crispr Therapeutics has a 1-year low of $24.56 and a 1-year high of $74.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. The firm has a 50 day simple moving average of $63.87 and a 200-day simple moving average of $50.25.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The business had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Equities analysts expect that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.
In other news, President Rodger Novak sold 33,618 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total value of $390,000.00. Following the completion of the sale, the director now directly owns 7,500 shares of the company’s stock, valued at $390,000. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 56,118 shares of company stock worth $3,620,760. Corporate insiders own 21.40% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Arbitrage SA acquired a new stake in shares of Crispr Therapeutics during the 2nd quarter valued at approximately $41,000. Aperio Group LLC acquired a new stake in shares of Crispr Therapeutics during the second quarter worth $153,000. Swiss National Bank lifted its position in shares of Crispr Therapeutics by 28.6% in the 2nd quarter. Swiss National Bank now owns 48,600 shares of the company’s stock worth $2,289,000 after buying an additional 10,800 shares during the last quarter. National Asset Management Inc. acquired a new position in shares of Crispr Therapeutics in the 2nd quarter valued at about $362,000. Finally, Wells Fargo & Company MN boosted its holdings in shares of Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after buying an additional 116,540 shares during the period. Institutional investors own 49.82% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: What is the Gross Domestic Product (GDP)?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.